How can you de-risk, save time, & reduce our drug development costs?

The complexity of drug design, in particular Antibody Drug Conjugates (ADCs), means that moving programs forward from discovery to market can be a challenging, costly and a cumbersome process. Technical, safety, stability and scalability hurdles must be overcome.

With the stakes higher than ever, having a trusted and experienced CDMO partner at each stage of development can help streamline the full pathway from discovery towards IND/CTA, and beyond. Over the past 20 years, Abzena has helped hundreds of customers achieve their regulatory milestones.

Leverage our extensive experience today in moving complex biologic and bioconjugate programs forward.